title: Predictors of outcome in patients with unresectable hepatocellular carcinoma receiving transcatheter arterial chemoembolization.
abstract: BACKGROUND
  Transcatheter arterial chemoembolization (TACE) has been shown to improve survival in patients with unresectable hepatocellular carcinoma (HCC).
  
  
  OBJECTIVE
  To identify pretreatment factors that predicts increased mortality in HCC patients receiving TACE.
  
  
  METHODS
  Retrospective review of all patients who underwent TACE for HCC from January 1999 to November 2004. Patient demographics, aetiology of liver disease, laboratory and imaging data regarding tumour characteristics were obtained.
  
  
  RESULTS
  Eighty-eight patients (57 +/- 1 years age) received 1-4 sessions of TACE (1.4 +/- 0.1). Tumour size was 3.3 +/- 0.2 cm (range 1-13 cm, median 3 cm) with mean number of lesions 1.9 +/- 0.1 (range 1-7). Mean model for the end stage liver disease score: 11 +/- 0.4; cancer of the liver Italian program score: 1.3 +/- 0.1. Survival post-TACE (excluding those underwent orthotopic liver transplantation) was 12 +/- 0.3 months. By multivariate analysis, tumour size (HR = 1.37, 95% CI: 1.11-1.68, P = 0.003), hypovascularity (HR = 12.62, 95% CI: 1.79-88.92, P = 0.01) and elevated international normalized ratio (HR = 1.46, 95% CI: 1.10-1.92 P = 0.008) are shown to be significant risk factors for increased mortality.
  
  
  CONCLUSIONS
  TACE therapy leads to a mean survival of 12 months in patients not receiving orthotopic liver transplantation. Tumour size, hypovascularity on imaging, and elevated international normalized ratio are predictors of increased mortality after TACE therapy for HCC.
authors.affiliation: Division of Gastroenterology/Hepatology, Department of Medicine, Indiana University, Indianapolis, IN 46202, USA.
authors.forename: H
authors.initials: H
authors.lastname: Shen
authors.forename: D
authors.initials: D
authors.lastname: Agarwal
authors.forename: R
authors.initials: R
authors.lastname: Qi
authors.forename: N
authors.initials: N
authors.lastname: Chalasani
authors.forename: S
authors.initials: S
authors.lastname: Liangpunsakul
authors.forename: L
authors.initials: L
authors.lastname: Lumeng
authors.forename: H
authors.initials: H
authors.lastname: Yoo
authors.forename: P
authors.initials: P
authors.lastname: Kwo
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000628:therapy*; D016461:Chemoembolization, Therapeutic / Q000401:mortality; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents